Actively Recruiting
A Pan-Asian Clinical Database of EGFR Exon 20 Insertion Mutated NSCLC
Led by National Cancer Centre, Singapore · Updated on 2025-06-12
600
Participants Needed
3
Research Sites
145 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
There are limited in depth studies on the epidemiology and clinical management of EGFR exon 20 insertion mutated NSCLC in Asia. In addition, there is preliminary data suggesting the exact location of the insertion and variant may influence the response and efficacy to novel EGFR targeted therapies. This study aims to fill this knowledge gap, by comprehensively characterising the epidemiology and clinical outcomes of Asian advanced EGFR exon 20 insertion mutated NSCLC patients.
CONDITIONS
Official Title
A Pan-Asian Clinical Database of EGFR Exon 20 Insertion Mutated NSCLC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically confirmed advanced NSCLC
- Positive test result for EGFR exon 20 insertion mutation using any locally approved test
- Diagnosis date between January 1, 2013 and December 31, 2024
- Male or female adults, age as defined by local regulations
You will not qualify if you...
- Patients without an EGFR exon 20 insertion mutation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
National Cancer Centre, Singapore
Singapore, Singapore, 168583
Actively Recruiting
2
Seoul National University Hospital
Seoul, South Korea
Actively Recruiting
3
National Taiwan University Hospital
Taipei, Taiwan
Actively Recruiting
Research Team
C
Cherlyn Shepherdson
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here